ALLIED BIOTECH CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.7 TWD | +2.61% |
|
-0.56% | +7.27% |
| 2023 | Allied Biotech Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | Allied Biotech Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2021 | 677M 20.8M | Sales 2022 | 717M 22.03M | Capitalization | 1.34B 41.19M |
|---|---|---|---|---|---|
| Net income 2021 | 13M 400K | Net income 2022 | 147M 4.52M | EV / Sales 2021 | 2.3 x |
| Net Debt 2021 | 105M 3.23M | Net Debt 2022 | 44.06M 1.35M | EV / Sales 2022 | 1.93 x |
| P/E ratio 2021 |
111
x | P/E ratio 2022 |
9.18
x | Employees | 40 |
| Yield 2021 |
3.28% | Yield 2022 |
8.54% | Free-Float | 71.92% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.61% | ||
| 1 week | -0.56% | ||
| Current month | -1.39% | ||
| 1 month | -1.12% | ||
| 3 months | +10.97% | ||
| 6 months | +7.27% | ||
| Current year | +7.27% |
1 week
17.15
18.00
1 month
17.1518.10
Current year
15.6018.30
1 year
13.5020.70
3 years
13.0520.70
5 years
13.0523.35
10 years
9.5428.79
| Managers | Title | Age | Since |
|---|---|---|---|
Ching Hui Lin
CEO | Chief Executive Officer | - | 01-11-30 |
Hsing Hui Yang
DFI | Director of Finance/CFO | - | - |
Pin Yang
PRN | Corporate Officer/Principal | - | 07-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yung Shun Chuang
BRD | Director/Board Member | - | 02-06-30 |
Ying Chieh Hsu
BRD | Director/Board Member | - | - |
Jung Min Kung
BRD | Director/Board Member | 80 | 02-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 17.7 | +2.61% | 38 001 |
| 24-04-18 | 17.25 | -3.90% | 104,791 |
| 24-04-17 | 17.95 | 0.00% | 62,221 |
| 24-04-16 | 17.95 | +2.28% | 118,342 |
| 24-04-15 | 17.55 | -1.96% | 21,000 |
End-of-day quote Taipei Exchange, April 18, 2024
More quotes
ALLIED BIOTECH CORPORATION is a Taiwan-based company principally engaged in the research and development, manufacturing and sales of carotenoid products and other nutraceutical products, manufacturing of precision chemical materials and manufacturing and wholesale of environmental medicines. The Company's nutraceutical products include healthcare products for human, nutraceutical products for animals, veterinary drugs, pharmaceutical cosmetics and biotechnology products, among others. Its carotenoids are applied in the processing of food and beverage products. Its major products include beta-carotene, canthaxanthin, lycopene, lutein, coenzyme Q10, natural vitamin E and food additives, among others. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, Europe and the Americas.
Sector
Food Processing
| 1st Jan change | Capi. | |
|---|---|---|
| +7.27% | 50.89M | |
| +4.07% | 7.38B | |
| -2.16% | 7.1B | |
| -2.13% | 5.88B | |
| -3.82% | 3.86B | |
| -16.25% | 3.24B | |
| -17.39% | 1.12B | |
| +5.02% | 894M | |
| -17.78% | 836M | |
| -18.12% | 790M |
- Stock Market
- Equities
- 1780 Stock
